Skip to content

Clinical trials

Consciousness Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Consciousness Disorders Clear all

279 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20022
20031
20045
20051
20061
20084
20092
20102
20113
20125
20132
201410
201517
201614
201714
201815
201912
202018
202123
202229
202319
202426
202521
202631

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed128
Unknown status56
Recruiting49
Not yet recruiting24
Terminated8
Active, not recruiting5
Enrolling by invitation5
Suspended2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
First Affiliated Hospital of Zhejiang University17
University of Liege17
Hangzhou Normal University13
Massachusetts General Hospital10
University of California, Los Angeles7
Xijing Hospital7
Assistance Publique - Hôpitaux de Paris6
Beijing Tiantan Hospital5
Fondazione Don Carlo Gnocchi ETS5
Hospices Civils de Lyon5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Consciousness Disorders279
Persistent Vegetative State62
Brain Injuries45
Brain Injuries, Traumatic37
Coma26
Anxiety Disorders21
Stroke16
Disease9
Major Depressive Disorder9
Cognitive Dysfunction6

Trials

Showing 26 to 50 of 279. Each trial links to its page on Pharma Observatory.

179 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.